Breast Cancer Highlights From ASCO 2026: ADCs, Biomarkers, and Earlier Treatment Strategies Take Center Stage
Amol Akhade: What The Devil Wears Prada 2 Taught Me About Oncology?
Alexandre Chan: Real-World Safety of Antibody–Drug Conjugates
IMMUNIB Study Uptades: Nivolumab Plus Lenvatinib in Unresectable HCC
Khizra Ahmad: Covering ASCO26 from Front-Row Seat as OncoDaily Ambassador
Hesham ElGhazaly: Meeting Global Oncology Leaders at ASCO 2026
Christopher Jackson: If Innovation Is the Heart of Oncology, Then Access Must Be Its Conscience
ESTRO-EORTC Expert Guideline on Target Delineation and Radiotherapy for Stage I–III Small Cell Lung Cancer
Tracks percentage of skeletal tumor burden and change from baseline in metastatic bone disease. Designed for longitudinal monitoring and documentation of disease trend.
Trend thresholds: Stable within ±10% of baseline | Increase >10% | Decrease >10%
